Drug Profile
Human factor IX biosimilar - GTC/LFB
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ProGenetics
- Developer LFB Biotechnologies; rEVO Biologics
- Class Blood coagulation factors; Recombinant proteins
- Mechanism of Action Factor IX stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia B
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-B in France (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-B in USA (Parenteral)
- 07 Dec 2010 GTC Biotherapeutics has been acquired by LFB Biotechnologies